Who We Are
Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators, to treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008.